Michael D. Blaszyk is Director at ImmunityBio, Inc. (IBRX). They have made 1 open-market trade across 1 company since 2023, most recently 2023-06-05.
CIK 0001371407
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $262K since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IBRX | BUY | 2023-06-05 | 2023-06-05 | $2.75 | $262K | -6.7% | -9.0% | -51.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.